CReATe Author Series: Ep. 3 - Dr. Michael Benatar and Neurofilament Biomarkers for ALS
Dec 22, 2021 ·
36m 32s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Dr. Michael Benatar is the Walter Bradley Chair in ALS Research, a Professor of Neurology at the University of Miami Miller School of Medicine and the Principal Investigator of the...
show more
Dr. Michael Benatar is the Walter Bradley Chair in ALS Research, a Professor of Neurology at the University of Miami Miller School of Medicine and the Principal Investigator of the CReATe Consortium. In this interview, he will discuss the CReATe Consortium’s recent paper titled "Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS". The interview highlights the specific ways in which validated biomarkers could benefit therapeutic development for ALS.
show less
Comments
Bill 3
2 years ago
Sorry, it enter to soon. It sounds very simple and without risk, simply draw blood. but... it needs to be adapted. but 20 years of testing and talking about it...
Bill 3
2 years ago
This apears to be wonderful news as a bio market and to evaluate treatmenst, but is is 10 or 20 years into the future until it is used?
Information
| Author | CReATe Consortium |
| Organization | CReATe Consortium |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
